Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

Core Insights - Nurix Therapeutics is advancing its potentially best-in-class BTK degrader, bexobrutideg, into pivotal clinical trials for relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and aims for global registration [1][2] - The company plans to expand bexobrutideg into autoimmune and inflammatory indications, targeting an IND submission in 2026 with a new tablet formulation [1][8] - Nurix is also advancing a portfolio of partnered inflammation and immunology programs, including IRAK4 and STAT6 degraders, leveraging its DEL-AI platform for drug discovery [1][6] 2025 Accomplishments and Highlights - In 2025, Nurix presented new clinical data showing an 83% objective response rate for bexobrutideg in CLL patients, with a median progression-free survival of 22.1 months [3][4] - The FDA's Project Optimus was successfully addressed with the selection of a 600 mg once-daily dose for pivotal development, which showed a trend toward improved efficacy without increased adverse events [3][4] - Nurix initiated the DAYBreak CLL-201 pivotal Phase 2 study in October 2025, evaluating bexobrutideg in patients with r/r CLL [4] Pipeline Advancements - The company introduced a new tablet formulation of bexobrutideg into Phase 1 testing to support an IND for inflammation and autoimmune indications [8] - Partner Gilead initiated Phase 1 testing of the IRAK4 degrader, GS-6791, while Sanofi advanced the STAT6 degrader program into IND enabling studies [8][9] - NX-1607, a first-in-class CBL-B inhibitor, demonstrated positive Phase 1a clinical data, indicating its potential as an immune-oncology agent [5][14] Financial Position and Leadership - Nurix strengthened its financial position by closing a registered offering of 24,485,799 shares, raising gross proceeds of $250 million, and earning $47 million in non-dilutive capital through collaborations [7][9] - The company appointed a new chief commercial officer and board members with extensive experience in drug development and commercialization [9] 2026 Outlook - Nurix aims to execute pivotal development pathways for bexobrutideg, including the initiation of a confirmatory Phase 3 study and further clinical studies in combination with other therapies [15] - The company plans to leverage its DEL-AI platform to fuel drug discovery programs and earn additional research milestones from collaborations [15]